Nalaganje...
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-L1) for a subset of cancer patients. PD-1 signaling negatively regulates T cell-mediated im...
Shranjeno v:
| izdano v: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6729004/ https://ncbi.nlm.nih.gov/pubmed/31488176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0779-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|